1. In Vivo

Dealmaking Quarterly Statistics, Q3 2020

A Look At M&A And Alliance Activity Across The Biopharma, Medical Device And In Vitro Diagnostics Industries, July-September 2020

 
• By Deanna Kamienski and Maureen Riordan

During Q3 biopharmas reached $41.7bn in merger and acquisition value and drew in $44.4bn in potential deal value from alliances. Device company M&A values reached $17.9bn while in vitro diagnostic firms and research tools players completed M&A activity that totaled $8.2bn.

Quarterly Stats_1200x675

Biopharma merger and acquisition value for the third quarter of 2020 reached $41.7bn, more than seven times Q2’s $5.9bn (see Exhibit 1). At the top (making up half of the Q3 total), was Gilead Sciences Inc.’s definitive agreement to acquire Immunomedics Inc. for approximately $21bn. Even if we take out that outlier, third quarter M&A still showed a significant increase over Q2. Where there were only two M&A transactions to hit the billion-dollar mark in Q2 (Novo Nordisk AS’s $2.1bn buy of private US biotech Corvidia Therapeutics and Alexion Pharmaceuticals Inc.’s buy of fellow public biotech Portola Pharmaceuticals Inc.), Q3 saw five such deals, four involving big pharma.

Through the Gilead/Immunomedics transaction, which is expected to close in Q4 2020, Gilead gains Immunomedics' Trodelvy (sacituzumab govitecan), making it...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

More from In Vivo

Rising Leaders 2025: Namrata Saroj On The Importance Of Authenticity In Ophthalmology

 
• By Sushmita Panda

Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.

Johnson & Johnson MedTech: How To Scale Digital Solutions

 
• By Natasha Barrow

J&J's EMEA head of digital solutions, Julia Fishman, talks about the hurdles in scaling digital innovation and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.

Rising Leaders 2025: Emma Hodcroft On Taking Initiative When “Plan A” Falls Short

 
• By Anabel Costa-Ferreira

Emma Hodcroft, co-founder of Pathoplexus and a key Nextstrain contributor, stresses the importance of career flexibility for young scientists. She urges early-stage researchers to embrace curiosity, using her unconventional path as an example of how curiosity can lead to impactful success.